Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS other · 2025-10-08Clinical Trial Update: A Rollover Study of CC-122 [Phase 1]
Rollover Phase 1 trial update for CC-122 in Non-Hodgkin Lymphoma; the study is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2025-10-07Clinical Trial Update: Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) [Phase 2, Phase 3]
Clinical trial update for the Stop Ig study, assessing whether antibiotic therapy or immunoglobulin use affects infection management and dec…
-
CLINICAL_TRIALS research · 2025-10-07Clinical Trial Update: Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) [Phase 2, Phase 3]
A Monash University trial is testing antibiotic therapy or intravenous immunoglobulin dosing to prevent infections in hematologic cancer pat…
-
CLINICAL_TRIALS research · 2025-10-07Clinical Trial Update: Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) [Phase 2, Phase 3]
A hematology platform trial (RATIONAL-PT) is evaluating the roles of antibiotic therapy or immunoglobulin for infections in patients with he…
-
CLINICAL_TRIALS other · 2025-10-07Clinical Trial Update: Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) [Phase 2, Phase 3]
Clinical trial update for Start Ig, a Phase 2/3 study investigating whether antibiotic therapy or intravenous immunoglobulin reduces infecti…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-10-06EMA Authorised: Rixathon (rituximab) — Sandoz GmbH
EMA authorised Rixathon (rituximab) by Sandoz as a biosimilar to Rituxan for several autoimmune and hematologic diseases, expanding access t…
-
CLINICAL_TRIALS trial_result · 2025-10-06Clinical Trial Update: Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia [Phase 1]
Phase 1 trial evaluating cellular immunotherapy after chemotherapy in patients with recurrent B-cell lymphoid cancers, including Non-Hodgkin…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma [Phase 1]
This update outlines a Phase 1 study of genetically modified T-cell infusions following peripheral blood stem cell transplant for patients w…
-
CLINICAL_TRIALS trial_result · 2025-10-06Clinical Trial Update: Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial [NA]
Clinical trial update confirming completion of the TECHS trial, which tested a telehealth exercise program to improve cardiovascular health …
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial [Phase 3]
Adaptive Phase 3 trial assessing optimized COVID-19 vaccination schedules for immunocompromised individuals, including patients with HIV and…
-
CLINICAL_TRIALS trial_result · 2025-10-02Clinical Trial Update: Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) [Phase 1]
Sana Biotechnology's investigational candidate SC291 is being studied in a Phase 1 ARDENT trial for relapsed/refractory B-cell malignancies,…
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
Expanded Access program for AVM0703 is available to eligible patients with several solid tumor and blood cancer indications, including gliob…
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies [Phase 1, Phase 2]
This clinical trial listing indicates that GNC-035 is being studied in relapsed or refractory non-Hodgkin lymphoma and other hematologic mal…
-
EMA approval · 2025-09-29EMA Authorised: Blitzima (rituximab) — Celltrion Healthcare Hungary Kft.
EMA authorized Blitzima (rituximab) from Celltrion Healthcare Hungary Kft. for non-Hodgkin lymphoma and chronic lymphocytic leukemia.
-
EMA approval · 2025-09-29EMA Authorised: Truxima (rituximab) — Celltrion Healthcare Hungary Kft.
EMA authorised Truxima (rituximab) by Celltrion Healthcare Hungary Kft. as a biosimilar rituximab for several indications including Non-Hodg…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update describes an ongoing Phase 1/2 study of selinexor in combination chemotherapy for advanced B-cell non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial update evaluating the combination of nivolumab and lenalidomide in relapsed or refractory lymphomas (non-Hodgkin an…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL [Phase 2]
A Phase 2 clinical trial evaluating the combination of linperlisib with cyclophosphamide, prednisone, and thalidomide (CPT) for relapsed/ref…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study of GNC-038 Injection in adults with relapsed or refractory Non-Hodgkin lymphoma, curr…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation [Phase 3]
A Phase 3 trial compares zanubrutinib plus rituximab against bendamustine plus rituximab in adults with previously untreated mantle cell lym…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies [EARLY_Phase 1]
An early-phase trial evaluating Darzalex Faspro (daratumumab and hyaluronidase-fihj) given before desensitization and allogeneic stem cell t…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL [Phase 1, Phase 2]
Clinical trial update for GNC-038 injection in Phase 1/2 studies for relapsed or refractory NK/T-cell lymphoma and Non-Hodgkin lymphoma, wit…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia [Phase 1]
Phase I clinical trial update for GNC-038 in non-Hodgkin lymphoma and acute lymphoblastic leukemia; the study is currently not recruiting.
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma [Phase 1]
This Phase 1 trial evaluates low-dose radiation as bridging therapy for relapsed or refractory B-cell non-Hodgkin lymphomas, including DLBCL…
-
CLINICAL_TRIALS trial_result · 2025-09-25Clinical Trial Update: Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study
The CREST study update shows the cardiovascular reserve evaluation trial in transplant survivors is currently active but not recruiting, spo…